An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Pyoderma Gangrenosum

In brief

The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).

Key facts

Study ID: NCT02326740
Run by: XOMA (US) LLC
People needed: 9
Starts: 2014-12-01
Expected to finish: 2016-03-01
Last updated by the study team: 2016-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

A clinical diagnosis of classic pyoderma gangrenosum
An active pyoderma gangrenosum ulcer
Contraceptive measures adequate to prevent pregnancy during the study

You may not qualify if…

Clinical evidence of acutely infected pyoderma gangrenosum
History of allergic or anaphylactic reactions to monoclonal antibodies
History of recurrent or chronic systemic infections
Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding
Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

Study site — Oceanside, California, United States
Study site — Tampa, Florida, United States
Study site — Macon, Georgia, United States
Study site — St Louis, Missouri, United States
Study site — Henderson, Nevada, United States
Study site — Rochester, New York, United States
Study site — The Bronx, New York, United States
Study site — Benowa, Queensland, Australia
Study site — Woolloongabba, Queensland, Australia
Study site — Parkville, Victoria, Australia
Study site — Fremantle, Australia
Study site — St Leonards, Australia
Study site — Sydney, Australia
Study site — Westmead, Australia
Study site — Markham, Ontario, Canada
Study site — Richmond Hill, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.